PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick, J. R. Siewert, Rainer Bredenkamp et al.|The Lancet Oncology|2007Cited by 808
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsM. Caplin, Zeng Zheng-Pei, Éric Baudin et al.|Annals of Oncology|2015Cited by 698
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric JunctionKatja Ott, Jörg‐Rüdiger Siewert, Wolfgang Weber et al.|Journal of Clinical Oncology|2006Cited by 464
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to TreatmentHinrich Wieder, Wolfgang Weber, Björn L.D.M. Brücher et al.|Journal of Clinical Oncology|2004Cited by 460
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective TrialKatja Ott, Wolfgang Weber, U. Fink et al.|Journal of Clinical Oncology|2003Cited by 320